The evoke and evoke+ trials are the first large-scale phase 3 studies testing whether oral semaglutide can modify the course of early-stage Alzheimer's disease in nearly 3,700 participants.
3,680 participantsThe evoke and evoke+ trials are among the largest Alzheimer's disease trials ever conducted, testing whether a GLP-1 drug already proven for diabetes and obesity can modify the course of dementia.
What the researchers found
This paper describes the design of evoke and evoke+ — two large-scale, randomized, double-blind, placebo-controlled phase 3 trials testing oral semaglutide (14 mg daily) as a disease-modifying treatment for early-stage Alzheimer's disease. Each trial targets 1,840 participants (3,680 total) aged 55-85 with mild cognitive impairment or mild dementia due to Alzheimer's confirmed by amyloid biomarkers. Treatment lasts 156 weeks (104-week main phase + 52-week blinded extension). The primary endpoint is change in Clinical Dementia Rating - Sum of Boxes (CDR-SB) at 104 weeks. The trials also explore effects on AD biomarkers and neuroinflammation through plasma and CSF sub-studies.
Why it matters
These are the first large-scale trials testing whether semaglutide — already widely used for diabetes and obesity — can modify the course of Alzheimer's disease. The hypothesis is that GLP-1 receptor agonists could protect the brain through anti-inflammatory, vascular, and neuroprotective mechanisms. If successful, this would be transformative: semaglutide has an established safety profile, is already mass-produced, and could be rapidly deployed for Alzheimer's — unlike the expensive and complex amyloid-targeting antibodies (lecanemab, donanemab) that currently dominate the field.
The numbers in context
3,680 planned participants (1,840 per trial) · 156 weeks treatment · Oral semaglutide 14 mg/day · CDR-SB primary endpoint · CSF sub-study n=210 · Enrollment: May 2021 - Sep 2023
How the study worked
Two parallel phase 3 RCTs with identical design. Eligible participants have early-stage symptomatic AD (MCI or mild dementia) with confirmed amyloid pathology (PET or CSF). After screening, participants are randomized 1:1 to oral semaglutide or placebo with an 8-week dose escalation (3mg → 7mg → 14mg). The primary endpoint is CDR-SB change from baseline to week 104. Secondary outcomes include AD biomarkers in plasma and CSF (neuroinflammation markers in a 210-participant sub-study).
Who was studied
3,680 adults aged 55-85 with early-stage symptomatic Alzheimer's disease (MCI or mild dementia) confirmed by amyloid biomarkers, randomized to oral semaglutide or placebo
What this study cannot tell us
This is a trial design paper — no results are reported yet. The trials enrolled participants with early-stage AD, so results won't address whether semaglutide helps moderate or advanced Alzheimer's. The oral formulation of semaglutide has lower bioavailability than injectable versions, which may affect brain penetration. The 104-week primary endpoint is lengthy, and dropout rates could be significant. The trial results were expected September 2025 and the extension October 2026.
How to read the evidence
This is a trial design paper describing two well-designed, large-scale, phase 3 RCTs. No results are available yet. The study design (double-blind, placebo-controlled, amyloid-confirmed population, validated primary endpoint) meets the highest standards of clinical trial methodology.
When this study was published
Published in 2025, this paper describes trials with main results expected around September 2025. By the time you read this, preliminary results may have been reported. These are among the most anticipated trial results in both the Alzheimer's and GLP-1 fields.
The bigger picture
Alzheimer's drug development has been dominated by amyloid-targeting antibodies, which are expensive, require infusions, and have modest effects with significant side effects (brain swelling and bleeding). The possibility that an oral GLP-1 drug with decades of safety data could modify Alzheimer's progression would fundamentally reshape the treatment landscape. Epidemiological data showing lower dementia rates in diabetic patients on GLP-1 drugs fueled this hypothesis, and these trials represent its definitive test.
Questions still open
- Will oral semaglutide achieve sufficient brain penetration to produce meaningful neuroprotective effects?
- If positive, would the injectable (higher bioavailability) form of semaglutide produce even greater effects in Alzheimer's?
- How will the results compare to amyloid-targeting antibodies like lecanemab and donanemab in terms of clinical benefit and safety?
Common questions
Why is a diabetes drug being tested for Alzheimer's?
When will we know if semaglutide works for Alzheimer's?
Read the original research
evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease.
Alzheimer's research & therapy, 17(1), 14
Citation
Cummings, Jeffrey L; Atri, Alireza; Feldman, Howard H; Hansson, Oskar; Sano, Mary; Knop, Filip K; Johannsen, Peter; León, Teresa; Scheltens, Philip. (2025). evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease.. Alzheimer's research & therapy, 17(1), 14. https://doi.org/10.1186/s13195-024-01666-7